Speakers
Sample of Keynote Speakers and their Case Studies
CASE STUDY
The Employer Experience Proposition
Global Internal Benchmark for key HR Metrics. Key HR Metrics are aggregated and shared globally between different regions so each region can compare their own results with others within Sony. This is a good use case of how own data is utilised and leveraged in a global scale.
- 01Digital marketing – More important than ever
- 02Commercial innovation
- 03Post-pandemic era: An accelerator of digital transformation
- 04Importance of developing the right content
- 05Future of pharma sales & marketing
- 06Customer centricityand customer engagement
CASE STUDY
The Employer Experience Proposition
Global Internal Benchmark for key HR Metrics. Key HR Metrics are aggregated and shared globally between different regions so each region can compare their own results with others within Sony. This is a good use case of how own data is utilised and leveraged in a global scale.
- 01Digital marketing – More important than ever
- 02Commercial innovation
- 03Post-pandemic era: An accelerator of digital transformation
- 04Importance of developing the right content
- 05Future of pharma sales & marketing
- 06Customer centricityand customer engagement
CASE STUDY
The Employer Experience Proposition
Global Internal Benchmark for key HR Metrics. Key HR Metrics are aggregated and shared globally between different regions so each region can compare their own results with others within Sony. This is a good use case of how own data is utilised and leveraged in a global scale.
- 01Digital marketing – More important than ever
- 02Commercial innovation
- 03Post-pandemic era: An accelerator of digital transformation
- 04Importance of developing the right content
- 05Future of pharma sales & marketing
- 06Customer centricityand customer engagement
CASE STUDY
Assessment of Benefit-Risk During Clinical Development
- 01The Regulator perspective on benefit-risk assessment during drug development
- 02Use of the structured benefit-risk assessment framework during drug development to inform milestone decisions
- 03Structured benefit-risk assessment during drug development — an evolving and iterative process to understand benefit-risk in a patient-centric manner
CASE STUDY
Unravelling the Complexity of Signal Detection and Risk Assessments on the Oncology Therapeutic Area
This presentation aims to emphasise the challenges of signal detection and risk assessments within the Oncology Therapeutic Area. In addition, it provides some useful insights on how to address some of the main challenges in this landscape.
- 01Highlight the main differences & challenges of Oncology vs other Therapeutical Areas
- 02Main challenges in signal detection in Oncology
- 03Consideration of benefit-risk balance in the combination setting in Oncology
CASE STUDY
Future of Pharmacovigilance Systems — Lessons Learned From COVID-19 Pandemic
COVID-19 pandemic started in late 2019 in China, expanding worldwide rapidly in early 2020. It resulted in 7 mln deaths. It became a novel challenge to the pharmacovigilance system worldwide for the whole pharma industry, particularly those parties that introduced vaccines against COVID-19. The development of vaccines and the unprecedented volume of ISRs reported in a short period of time after mass vaccination programmes started resulted in various types of challenges that required new ways of managing data, risk, reporting, controls and application of new technologies. The pandemic provided lessons learned that impacted the future of effective pharmacovigilance systems.
- 01Pharmacovigilance conditions evolution during the COVID-19 pandemic
- 02EU countries’ role in generating vaccine ICSRs volumes
- 03Increasing role of patients/customers engagement in PV system and case volume
- 04Regulatory framework landscape changes and increase of national requirements
- 05Social media as the preferred communication channel for safety/efficacy topics and its implication for PV system
- 06Novel technologies application across all PV activities
CASE STUDY
The Pitfalls of the EU PSMF
- 01How insufficient attention to detail leads to errors, omissions, or inaccuracies in the PSMF?
- 02Cross-functional collaboration, a key aspect often forgotten
- 03Failure to update the PSMF, now what?
CASE STUDY
Innovations in Global Drug Safety: A Comprehensive Approach to Risk Management and Pharmacovigilance
- 01Balancing time, cost and quality to maximise overall outcomes
- 02Driving process optimisation in order to accelerate to value!
- 03Harnessing the team to achieve excellence
CASE STUDY
Assessment of Benefit-Risk During Clinical Development
- 01The Regulator perspective on benefit-risk assessment during drug development
- 02Use of the structured benefit-risk assessment framework during drug development to inform milestone decisions
- 03Structured benefit-risk assessment during drug development — an evolving and iterative process to understand benefit-risk in a patient-centric manner
CASE STUDY
Unravelling the Complexity of Signal Detection and Risk Assessments on the Oncology Therapeutic Area
This presentation aims to emphasise the challenges of signal detection and risk assessments within the Oncology Therapeutic Area. In addition, it provides some useful insights on how to address some of the main challenges in this landscape.
- 01Highlight the main differences & challenges of Oncology vs other Therapeutical Areas
- 02Main challenges in signal detection in Oncology
- 03Consideration of benefit-risk balance in the combination setting in Oncology
CASE STUDY
Innovations in Global Drug Safety: A Comprehensive Approach to Risk Management and Pharmacovigilance
- 01Balancing time, cost and quality to maximise overall outcomes
- 02Driving process optimisation in order to accelerate to value!
- 03Harnessing the team to achieve excellence
CASE STUDY
The Pitfalls of the EU PSMF
- 01How insufficient attention to detail leads to errors, omissions, or inaccuracies in the PSMF?
- 02Cross-functional collaboration, a key aspect often forgotten
- 03Failure to update the PSMF, now what?
CASE STUDY
Future of Pharmacovigilance Systems — Lessons Learned From COVID-19 Pandemic
COVID-19 pandemic started in late 2019 in China, expanding worldwide rapidly in early 2020. It resulted in 7 mln deaths. It became a novel challenge to the pharmacovigilance system worldwide for the whole pharma industry, particularly those parties that introduced vaccines against COVID-19. The development of vaccines and the unprecedented volume of ISRs reported in a short period of time after mass vaccination programmes started resulted in various types of challenges that required new ways of managing data, risk, reporting, controls and application of new technologies. The pandemic provided lessons learned that impacted the future of effective pharmacovigilance systems.
- 01Pharmacovigilance conditions evolution during the COVID-19 pandemic
- 02EU countries’ role in generating vaccine ICSRs volumes
- 03Increasing role of patients/customers engagement in PV system and case volume
- 04Regulatory framework landscape changes and increase of national requirements
- 05Social media as the preferred communication channel for safety/efficacy topics and its implication for PV system
- 06Novel technologies application across all PV activities
CASE STUDY
Assessment of Benefit-Risk During Clinical Development
- 01The Regulator perspective on benefit-risk assessment during drug development
- 02Use of the structured benefit-risk assessment framework during drug development to inform milestone decisions
- 03Structured benefit-risk assessment during drug development — an evolving and iterative process to understand benefit-risk in a patient-centric manner
CASE STUDY
Unravelling the Complexity of Signal Detection and Risk Assessments on the Oncology Therapeutic Area
This presentation aims to emphasise the challenges of signal detection and risk assessments within the Oncology Therapeutic Area. In addition, it provides some useful insights on how to address some of the main challenges in this landscape.
- 01Highlight the main differences & challenges of Oncology vs other Therapeutical Areas
- 02Main challenges in signal detection in Oncology
- 03Consideration of benefit-risk balance in the combination setting in Oncology
CASE STUDY
The Pitfalls of the EU PSMF
- 01How insufficient attention to detail leads to errors, omissions, or inaccuracies in the PSMF?
- 02Cross-functional collaboration, a key aspect often forgotten
- 03Failure to update the PSMF, now what?
CASE STUDY
Future of Pharmacovigilance Systems — Lessons Learned From COVID-19 Pandemic
COVID-19 pandemic started in late 2019 in China, expanding worldwide rapidly in early 2020. It resulted in 7 mln deaths. It became a novel challenge to the pharmacovigilance system worldwide for the whole pharma industry, particularly those parties that introduced vaccines against COVID-19. The development of vaccines and the unprecedented volume of ISRs reported in a short period of time after mass vaccination programmes started resulted in various types of challenges that required new ways of managing data, risk, reporting, controls and application of new technologies. The pandemic provided lessons learned that impacted the future of effective pharmacovigilance systems.
- 01Pharmacovigilance conditions evolution during the COVID-19 pandemic
- 02EU countries’ role in generating vaccine ICSRs volumes
- 03Increasing role of patients/customers engagement in PV system and case volume
- 04Regulatory framework landscape changes and increase of national requirements
- 05Social media as the preferred communication channel for safety/efficacy topics and its implication for PV system
- 06Novel technologies application across all PV activities
CASE STUDY
Innovations in Global Drug Safety: A Comprehensive Approach to Risk Management and Pharmacovigilance
- 01Balancing time, cost and quality to maximise overall outcomes
- 02Driving process optimisation in order to accelerate to value!
- 03Harnessing the team to achieve excellence